Vector Labs Ab03376-10.3 Anti-CD127 [1A11 H3L4], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 1A11 H3L4
Heavy Chain Modification: Fc Silent™
Synonyms: IL7R; IL-7RA; CDw127; Interleukin-7 receptor subunit alpha; IL-7 receptor subunit alpha; IL-7R subunit alpha; IL-7R-alpha; GSK2618960
Amount: 200 μg
Application Codes Clone: inhibit; ELISA; immunotherapy
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody binds the alpha component of the human IL-7RA (CD127). This antibody also cross reacts with cynomolgus monkey and marmoset IL-7Ra. This protein acts as a receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). Binding of IL-7 to the IL-7R activates multiple signaling pathways including the activation of JAK kinases 1 and 3 leading to the phosphorylation and activation of Stat5. Another IL-7R mediated pathway is the activation of PI3 kinase, resulting in the phosphorylation of the pro-apoptotic protein Bad and its cytoplasm retention. CD127 is expressed in peripheral resting and memory T cells.
Application Notes: The binding affinity of this antibody for human interleukin 7 receptor was determined using BIACORE analysis and was reported to be Kd= 22 pM. This antibody demonstrated complement dependent cytotoxicity on HEK293 cells expressing hIL-7R in vitro. This antibody showed inhibition of IL-7-induced STAT5 phosphorylation in human polymorphonuclear monocytes and IL-17 production in differentiated human Th17 cells in an in vitro assay (US9150653). The safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of this antibody was studied in healthy subjects. Single doses of this antibody (0.6 mg kg–1 or 2.0 mg kg–1) were well tolerated, increased circulating IL‐7 and soluble CD127, and elicited antidrug antibodies with neutralizing capability, but did not have an impact on lymphocyte populations, inflammatory cytokines or differentiation markers. It blocked IL-7 receptor signaling upon full target engagement. This antibody may effectively modulate the autoinflammatory activity of pathogenic T cells in diseased tissue (PMID: 30161291). The characterization of humoral response generated after administration of this antibody was studied in a single-dose escalation phase I study (PMID: 33755713).

Product Class:	Purified
Clone ID:	1A11 H3L4
Heavy Chain Modification:	Fc Silent™
Synonyms:	IL7R; IL-7RA; CDw127; Interleukin-7 receptor subunit alpha; IL-7 receptor subunit alpha; IL-7R subunit alpha; IL-7R-alpha; GSK2618960
Amount:	200 μg
Application Codes Clone:	inhibit; ELISA; immunotherapy
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody binds the alpha component of the human IL-7RA (CD127). This antibody also cross reacts with cynomolgus monkey and marmoset IL-7Ra. This protein acts as a receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). Binding of IL-7 to the IL-7R activates multiple signaling pathways including the activation of JAK kinases 1 and 3 leading to the phosphorylation and activation of Stat5. Another IL-7R mediated pathway is the activation of PI3 kinase, resulting in the phosphorylation of the pro-apoptotic protein Bad and its cytoplasm retention. CD127 is expressed in peripheral resting and memory T cells.
Application Notes:	The binding affinity of this antibody for human interleukin 7 receptor was determined using BIACORE analysis and was reported to be Kd= 22 pM. This antibody demonstrated complement dependent cytotoxicity on HEK293 cells expressing hIL-7R in vitro. This antibody showed inhibition of IL-7-induced STAT5 phosphorylation in human polymorphonuclear monocytes and IL-17 production in differentiated human Th17 cells in an in vitro assay (US9150653). The safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of this antibody was studied in healthy subjects. Single doses of this antibody (0.6 mg kg–1 or 2.0 mg kg–1) were well tolerated, increased circulating IL‐7 and soluble CD127, and elicited antidrug antibodies with neutralizing capability, but did not have an impact on lymphocyte populations, inflammatory cytokines or differentiation markers. It blocked IL-7 receptor signaling upon full target engagement. This antibody may effectively modulate the autoinflammatory activity of pathogenic T cells in diseased tissue (PMID: 30161291). The characterization of humoral response generated after administration of this antibody was studied in a single-dose escalation phase I study (PMID: 33755713).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews